IRCT20171030037093N11招募中3 期
The evaluation of the effect of linagliptin on microalbuminuria in type 2 diabetes patients with nephropathy
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with 6.5% to 10% glycated hemoglobin (hemoglobin HbA1c) (48 to 86 mmol / mol)
- •Patients with BMI = 40 kg / m²
- •The level of albumin to creatinine (UACR) ranged from 30 to 3000 mg / g creatinine (in three urine samples consecutive two weeks before the start of the study)
排除标准
- •Patients who consumed rapid acting insulin, rosiglitazone, pioglitazone, GLP-1 analogues, or anti-obesity drugs three months before the start of the study
- •Patients who had myocardial infarction, stroke, or transient ischemic attack six months before the start of the study.
- •Patients with non-diabetic renal insufficiency or urinary tract infection
- •Patients who have received kidney transplants
研究者
相似试验
招募中
3 期
Effect of Linagliptin on Diabetic patients with COVID-19COVID-19.COVID-19, virus identifiedU07.1IRCT20210812052156N1Gonabad University of Medical Sciences70
招募中
2 期
Effect of Linagliptin and Empagliflozine on diabetesIRCT20221016056201N1Arak University of Medical Sciences55
进行中（未招募）
1 期
Study on the positive effects of treatment with linagliptin on the arteries of patients with diabetestype 2 diabetes mellitusMedDRA version: 17.1Level: LLTClassification code 10045252Term: Type II diabetes mellitus without mention of complicationSystem Organ Class: 100000004861EUCTR2012-005220-15-NLniversity Medical Center Groningen
已完成
3 期
Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early diabetesDiabetes Mellitus type 2Type 2 diabetes10018424NL-OMON40278niversitair Medisch Centrum Groningen45
进行中（未招募）
1 期
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients with Type 2 Diabetes Mellitus on Stable Metformin TreatmentType 2 Diabetes MellitusEUCTR2014-004895-48-DEProfil Institut für Stoffwechselforschung GmbH